Peer-influenced content. Sources you trust. No registration required. This is HCN.
British Medical Journal
A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.
Psychiatry September 10th 2024
Psych Congress Network
Clinicians treating cancer and kidney disease patients prescribed antidepressants at rates similar to outpatient psychiatrists, highlighting the prevalence of depression management across specialties.
Psychiatry August 14th 2024
The New England Journal of Medicine
In this NEJM Double Take episode, experts discuss the critical role of neuroplasticity in depression and examine advanced treatment options for patients who do not respond to traditional therapies. Topics include the efficacy of ECT and TMS, as well as emerging evidence for ketamine, esketamine, and psilocybin.
Psychiatry June 4th 2024
MDLinx
The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.
Psychiatry May 28th 2024
Psychiatry Advisor
Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.
Psychiatry May 21st 2024
Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.
Psychiatry May 7th 2024